Skip to content
10-Q

Quarterly Report

TONGLI PHARMACEUTICALS (USA), INC.

0001144204-14-009153

← back to feed
Filed
Feb 14, 2014 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2013 · Feb 8, 2014 14.73M sh
Operating Cash Flow Q3 2013 · Dec 31, 2013 $1.98M
Operating Cash Flow Q3 2013 · Dec 31, 2012 $4.71M
Stockholders Equity Q3 2013 · Dec 31, 2013 $20.74M
Stockholders Equity Q3 2013 · Mar 31, 2013 $20.47M
Current Liabilities Q3 2013 · Dec 31, 2013 $859.33K
Current Liabilities Q3 2013 · Mar 31, 2013 $1.59M
Current Assets Q3 2013 · Dec 31, 2013 $1.35M
Current Assets Q3 2013 · Mar 31, 2013 $4.07M
Total Assets Q3 2013 · Dec 31, 2013 $21.6M
Total Assets Q3 2013 · Mar 31, 2013 $22.06M
Sga Expense Q3 2013 · Dec 31, 2013 $73.22K
Sga Expense Q3 2013 · Dec 31, 2013 $274.35K
Sga Expense Q3 2013 · Dec 31, 2012 $130.49K
Sga Expense Q3 2013 · Dec 31, 2012 $764.21K
Net Income Q3 2013 · Dec 31, 2013 −$180.14K
Net Income Q3 2013 · Dec 31, 2013 −$297.89K
Net Income Q3 2013 · Dec 31, 2012 $1.32M
Net Income Q3 2013 · Dec 31, 2012 $1.63M
Operating Income Q3 2013 · Dec 31, 2013 −$208.6K
Operating Income Q3 2013 · Dec 31, 2013 −$300.08K
Operating Income Q3 2013 · Dec 31, 2012 $1.79M
Operating Income Q3 2013 · Dec 31, 2012 $2.33M
Gross Profit Q3 2013 · Dec 31, 2013 $0
Gross Profit Q3 2013 · Dec 31, 2013 $373.96K
Gross Profit Q3 2013 · Dec 31, 2012 $2.02M
Gross Profit Q3 2013 · Dec 31, 2012 $3.6M
Cost Of Revenue Q3 2013 · Dec 31, 2013 $0
Cost Of Revenue Q3 2013 · Dec 31, 2013 $381.51K
Cost Of Revenue Q3 2013 · Dec 31, 2012 $1.73M
Cost Of Revenue Q3 2013 · Dec 31, 2012 $3.48M